Add to ORKGBackground. Parenteral artesunate is recommended as first-line therapy for severe malaria. While its efficacy is firmly established, data on safety are still incomplete. Delayed hemolysis has been described in hyperparasitemic nonimmune travelers, but it is unknown if African children are equally at risk. Methods. Children aged 6 to 120 months with severe malaria were followed up after treatment with parentera
Current artesunate (ARS) regimens for severe malaria are complex. Once daily intramuscular (i.m.) in...
BACKGROUND: Malaria is a leading cause of mortality, particularly in sub-Saharan African children. P...
Parenteral artesunate (ARS) is the drug of choice for the treatment of severe malaria. Pharmacokinet...
Background. Parenteral artesunate is recommended as first-line therapy for severe malaria. While its...
Background Parenteral artesunate is the treatment of choice for severe malaria. Recently, haemolytic...
Parenteral artesunate for the treatment of severe malaria in non-immune travelers is associated with...
Parenteral artesunate (AS) is the WHO first-line treatment recommended in adults and children for se...
International audienceBackground: Parenteral artesunate is recommended as first-line therapy for sev...
Cases of delayed hemolytic anemia have been described after treatment with injectable artesunate, th...
Artesunate is the drug of choice for treating patients with severe malaria. Post-artesunate delayed ...
INTRODUCTION: Delayed haemolytic anaemia is one of the more frequent events after tr...
Abstract Parenteral artesunate has been shown to be a superior treatment option compared to parenter...
Artesunate is the most effective treatment for severe malaria. However, delayed-onset hemolytic anem...
Malaria is a serious and sometimes fatal disease caused by an intraerythrocytic parasite, and is com...
Parenteral artesunate (AS) is the WHO first-line treatment recommended in adults and children for se...
Current artesunate (ARS) regimens for severe malaria are complex. Once daily intramuscular (i.m.) in...
BACKGROUND: Malaria is a leading cause of mortality, particularly in sub-Saharan African children. P...
Parenteral artesunate (ARS) is the drug of choice for the treatment of severe malaria. Pharmacokinet...
Background. Parenteral artesunate is recommended as first-line therapy for severe malaria. While its...
Background Parenteral artesunate is the treatment of choice for severe malaria. Recently, haemolytic...
Parenteral artesunate for the treatment of severe malaria in non-immune travelers is associated with...
Parenteral artesunate (AS) is the WHO first-line treatment recommended in adults and children for se...
International audienceBackground: Parenteral artesunate is recommended as first-line therapy for sev...
Cases of delayed hemolytic anemia have been described after treatment with injectable artesunate, th...
Artesunate is the drug of choice for treating patients with severe malaria. Post-artesunate delayed ...
INTRODUCTION: Delayed haemolytic anaemia is one of the more frequent events after tr...
Abstract Parenteral artesunate has been shown to be a superior treatment option compared to parenter...
Artesunate is the most effective treatment for severe malaria. However, delayed-onset hemolytic anem...
Malaria is a serious and sometimes fatal disease caused by an intraerythrocytic parasite, and is com...
Parenteral artesunate (AS) is the WHO first-line treatment recommended in adults and children for se...
Current artesunate (ARS) regimens for severe malaria are complex. Once daily intramuscular (i.m.) in...
BACKGROUND: Malaria is a leading cause of mortality, particularly in sub-Saharan African children. P...
Parenteral artesunate (ARS) is the drug of choice for the treatment of severe malaria. Pharmacokinet...